J Physiol Wellcome Trust-funded researchers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 583, Number 3, 1155-1163, September 15, 2007 DOI: 10.1113/jphysiol.2007.137216
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
583/3/1155    most recent
jphysiol.2007.137216v1
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simmons, G. H.
Right arrow Articles by Halliwill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simmons, G. H.
Right arrow Articles by Halliwill, J. R.
Related Collections
Right arrow Integrative

INTEGRATIVE

Mild central chemoreflex activation does not alter arterial baroreflex function in healthy humans

Grant H. Simmons1, Julie M. Manson1 and John R. Halliwill1

1 Department of Human Physiology, University of Oregon, Eugene, Oregon 97403-1240, USA

We have previously shown that activation of peripheral chemoreceptors with isocapnic hypoxia resets arterial baroreflex control of heart rate and sympathetic vasoconstrictor outflow to higher pressures, without changes in baroreflex gain. We tested the hypothesis that activation of central chemoreceptors with mild hyperoxic hypercapnia also causes resetting of the arterial baroreflex, but that this resetting would not occur with matched volume and frequency hyperpnoea. Baroreflex control of heart rate (n = 16) and muscle sympathetic nerve activity (microneurography; n = 11) was assessed in healthy men and women, age 20–33 years, using the modified Oxford technique during hyperoxic eucapnia, hyperoxic hyperpnoea and hyperoxic hypercapnia (end-tidal PCO2 + 5 mmHg above eucapnia). Baroreflex trials were separated by 30 min of rest. While neither hyperpnoea nor hypercapnia changed mean arterial pressure (92.0 ± 1.8 during eucapnia versus 91.0 ± 1.2 and 90.7 ± 1.4 mmHg during hyperpnoea and hypercapnia; P = 0.427) or muscle sympathetic nerve activity (2301 ± 687 during eucapnia versus 2959 ± 987 and 2272 ± 414 total integrated units min–1 during hyperpnoea and hypercapnia; P = 0.653), heart rate was increased from 59.3 ± 2.7 during eucapnia to 63.2 ± 3.0 and 62.4 ± 2.8 beats min–1 during hyperpnoea and hypercapnia (both P < 0.017). Baroreflex gain was not altered by hyperpnoea or hypercapnia. Thus, acute activation of central chemoreceptors with mild hyperoxic hypercapnia does not affect arterial pressure, sympathetic vasoconstrictor outflow, or baroreflex gain. Heart rate is elevated during hyperoxic hypercapnia, but this response is not different from the increase in heart rate produced by matched volume and frequency hyperpnoea. Therefore, mild activation of central chemoreceptors does not appear to alter arterial baroreflex function.

(Received 23 May 2007; accepted after revision 18 July 2007; first published online 19 July 2007)
Corresponding author J. R. Halliwill: 122 Esslinger Hall, 1240 University of Oregon, Eugene, OR 97403-1240, USA. Email: halliwil{at}uoregon.edu







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 The Physiological Society.